中华医学杂志(英文版)
中華醫學雜誌(英文版)
중화의학잡지(영문판)
CHINESE MEDICAL JOURNAL
2002年
12期
1849-1854
,共6页
侯芳%李家泰%吴国平%郑波%陈亦芳%顾俊明%王慧玲%霍丽%薜欣%贾长绪%尹永红%田晓峰%任双义
侯芳%李傢泰%吳國平%鄭波%陳亦芳%顧俊明%王慧玲%霍麗%薜訢%賈長緒%尹永紅%田曉峰%任雙義
후방%리가태%오국평%정파%진역방%고준명%왕혜령%곽려%벽흔%가장서%윤영홍%전효봉%임쌍의
美罗培南%泰能%感染
美囉培南%泰能%感染
미라배남%태능%감염
meropenem%imipenem/cilastatin%infection
目的评价美罗培南的安全性和有效性.方法共入选182例,其中试验组90例,疗效评价70例,不良反应评价72例;对照组92例,疗效评价70例,不良反应评价70例.组药方法为美罗培南500 mg/次,Q12 h (必要时1 g,Q12 h),静脉点滴30分钟;泰能(亚胺培南/西司他丁,500 mg/500 mg),500 mg/次,Q 12 h(必要时1 g, Q12 h),静脉点滴30分钟,疗程均为7-14天.结果两药临床有效率分别为90%与87%,细菌清除率分别为86%(55/64)和86%(57/66),76%(93/123)的临床分离致病菌进行株致病菌产β-内酰胺酶阳性.不良反应发生率分别为9.7%(7/72)与8.6%(6/70).以上结果经统计学处理无显著差异(P>0.05).结论美罗培南治疗细菌性感染(包括酶菌感染)安全有效.
目的評價美囉培南的安全性和有效性.方法共入選182例,其中試驗組90例,療效評價70例,不良反應評價72例;對照組92例,療效評價70例,不良反應評價70例.組藥方法為美囉培南500 mg/次,Q12 h (必要時1 g,Q12 h),靜脈點滴30分鐘;泰能(亞胺培南/西司他丁,500 mg/500 mg),500 mg/次,Q 12 h(必要時1 g, Q12 h),靜脈點滴30分鐘,療程均為7-14天.結果兩藥臨床有效率分彆為90%與87%,細菌清除率分彆為86%(55/64)和86%(57/66),76%(93/123)的臨床分離緻病菌進行株緻病菌產β-內酰胺酶暘性.不良反應髮生率分彆為9.7%(7/72)與8.6%(6/70).以上結果經統計學處理無顯著差異(P>0.05).結論美囉培南治療細菌性感染(包括酶菌感染)安全有效.
목적평개미라배남적안전성화유효성.방법공입선182례,기중시험조90례,료효평개70례,불량반응평개72례;대조조92례,료효평개70례,불량반응평개70례.조약방법위미라배남500 mg/차,Q12 h (필요시1 g,Q12 h),정맥점적30분종;태능(아알배남/서사타정,500 mg/500 mg),500 mg/차,Q 12 h(필요시1 g, Q12 h),정맥점적30분종,료정균위7-14천.결과량약림상유효솔분별위90%여87%,세균청제솔분별위86%(55/64)화86%(57/66),76%(93/123)적림상분리치병균진행주치병균산β-내선알매양성.불량반응발생솔분별위9.7%(7/72)여8.6%(6/70).이상결과경통계학처리무현저차이(P>0.05).결론미라배남치료세균성감염(포괄매균감염)안전유효.
Objective To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections. Methods A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7-14 days for both groups. Results Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced β-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P>0.05). Conclusion Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains.
